Developers back Alzheimer’s drugs despite report suggesting lack of efficacy
Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less…
16 Apr 2026
Lilly debuts more Foundayo data as FDA requests post-marketing trials
Eli Lilly has released more data for its obesity pill, Foundayo (orforglipron) in a rapid response to US regulators voicing certain reservations on the therapy's safety. In a new drug…
16 Apr 2026
Terremoto wins $108m in Series C to drive cancer and rare disease programmes
Terremoto Biosciences has closed a Series C financing round worth $108m, which will allow the company to usher its range of AKT-1 selective inhibitors through early clinical development across multiple…
16 Apr 2026
Nucleai and Sirona Dx to provide new proteomics solution for pharma companies
Nucleai has partnered with Sirona Dx to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology businesses for drug development. The collaboration aims to bridge gaps between data generation…
16 Apr 2026
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer (ES-SCLC) and other…
15 Apr 2026
FDA shares guide on genome editing best practices
The US Food and Drug Administration (FDA) has debuted draft guidance for gene therapy developers, focused on the use of genome editing technologies in non-clinical studies. This framework, introduced by…
15 Apr 2026
Amazon launches AI drug discovery platform
Amazon Web Services (AWS) is launching an artificial intelligence (AI) application to design and test novel drugs more quickly and confidently. The system, called Amazon Bio Discovery, gives researchers direct…